Avoid common mistakes on your manuscript.
Correction to: Diabetes Ther (2020) 11:1017–1027 https://doi.org/10.1007/s13300-020-00781-6
In the original publication, the timing of baseline CGM assessment was incorrectly stated in the text in two instances; it is correct in Fig. 1.
In the “Data Collection” section, the sentence “Baseline and investigational CGM values are assessed during weeks 0–3 and 9–12, respectively…” should state “Baseline and investigational CGM values are assessed during weeks −3 to 0 and 9 to 12, respectively…”
In the “Statistical Analysis” section, the sentence “The percentage of time in the glucose range of ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L) at week 12 will be assessed in both arms using 20 days of blinded CGM data during weeks 0–3 and 9–12” should state “The percent time in the glucose range of ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L) at week 12 will be assessed using data generated during the randomised period.”
Open Access
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Battelino, T., Bosnyak, Z., Danne, T. et al. Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design. Diabetes Ther 11, 1607–1608 (2020). https://doi.org/10.1007/s13300-020-00820-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-020-00820-2